• Dual anti-platelet therapy in secondary stroke prevention

  • 著者： Springer Healthcare IME
  • ポッドキャスト

Dual anti-platelet therapy in secondary stroke prevention

著者： Springer Healthcare IME
無料で聴く

  • サマリー

  • Professor Marc Fisher and Springer Healthcare IME invite you to listen to these three podcast discussions with experts in this therapy area. The podcasts focus on the clinical implications of recently published results from clinical trials involving the use of dual-anti-platelet therapy for secondary stroke prevention.
    Springer Healthcare. Part of the Springer Nature Group.
    続きを読む 一部表示

あらすじ・解説

Professor Marc Fisher and Springer Healthcare IME invite you to listen to these three podcast discussions with experts in this therapy area. The podcasts focus on the clinical implications of recently published results from clinical trials involving the use of dual-anti-platelet therapy for secondary stroke prevention.
Springer Healthcare. Part of the Springer Nature Group.
生物科学 衛生・健康的な生活 身体的病い・疾患
続きを読む 一部表示
エピソード
  • Discussion of the CHANCE and PRINCE clinical trials (with Marc Fisher and Liping Liu)

    Discussion of the CHANCE and PRINCE clinical trials (with Marc Fisher and Liping Liu)
    2021/03/02

    Professors Marc Fisher and Liping Liu discuss the CHANCE and PRINCE clinical trials focusing on their backgrounds and key results, and commenting on their clinical implications.

    This programme is made possible thanks to an independent educational grant from AstraZeneca.

    Find more information at https://ime.springerhealthcare.com/programs/emerging-dual-anti-platelet-therapy-strategies-for-neurologists-in-secondary-stroke-prevention/
    続きを読む 一部表示
    18 分
  • Discussion on the POINT trial (with Marc Fisher and Greg Albers)

    Discussion on the POINT trial (with Marc Fisher and Greg Albers)
    2021/03/02

    Professor Marc Fisher and Dr Greg Albers discuss the POINT trial, also commenting on when to consider ticagrelor versus clopidogrel.

    This programme is made possible thanks to an independent educational grant from AstraZeneca.

    Find more information at https://ime.springerhealthcare.com/programs/emerging-dual-anti-platelet-therapy-strategies-for-neurologists-in-secondary-stroke-prevention/
    続きを読む 一部表示
    18 分
  • Discussion on the THALES trial and the clinical implications of the CHANCE 2 trial (with Marc Fisher and Clay Johnston)

    Discussion on the THALES trial and the clinical implications of the CHANCE 2 trial (with Marc Fisher and Clay Johnston)
    2021/03/02

    Professor Marc Fisher and Dr Clay Johnston discuss the THALES trial, explaining its rationale, key results and subgroup analyses, and also comment on the potential clinical implications of CHANCE 2.

    This programme is made possible thanks to an independent educational grant from AstraZeneca.

    Find more information at https://ime.springerhealthcare.com/programs/emerging-dual-anti-platelet-therapy-strategies-for-neurologists-in-secondary-stroke-prevention/
    続きを読む 一部表示
    22 分

Dual anti-platelet therapy in secondary stroke preventionに寄せられたリスナーの声

カスタマーレビュー：以下のタブを選択することで、他のサイトのレビューをご覧になれます。

Audible.co.jp

Amazon.co.jp
レビューはまだありません。